2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Multiple Myeloma
809
Precursor Cell Lymphoblastic Leukemia-Lymphoma
171
Recurrence
141
Neoplasms, Plasma Cell
111
Lymphoma
93
Leukemia
91
Neoplasms
81
Burkitt Lymphoma
57
Vomiting
51
Lymphoma, Non-Hodgkin
50
Immunoglobulin Light-chain Amyloidosis
50
Lymphoma, Large B-Cell, Diffuse
44
Nausea
38
Lymphoma, Mantle-Cell
38
Prostatic Neoplasms
31
Lymphoma, Follicular
30
Hodgkin Disease
29
Waldenstrom Macroglobulinemia
27
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
27
Neoplasm Metastasis
26
Leukemia, Lymphocytic, Chronic, B-Cell
26
Carcinoma, Non-Small-Cell Lung
26
Leukemia, Myeloid, Acute
25
Breast Neoplasms
25
Lung Neoplasms
23
Amyloidosis
21
Leukemia, Biphenotypic, Acute
18
Lymphoma, B-Cell, Marginal Zone
17
Lymphoma, Extranodal NK-T-Cell
16
Smoldering Multiple Myeloma
15
Interventions
Etoposide
6
Vincristine
5
Prednisone
5
Doxorubicin
5
Cyclophosphamide
5
Rituximab
4
prednylidene
3
deltacortene
3
daratumumab
2
Cytarabine
2
varlilumab
1
pomalidomide
1
merphos
1
ixazomib
1
carmustine, poliferprosan 20 drug combination
1
belantamab mafodotin
1
Vorinostat
1
Specimen Handling
1
Peripheral Blood Stem Cell Transplantation
1
Nivolumab
1
Methotrexate
1
Melphalan
1
Magnetic Resonance Spectroscopy
1
Immunoglobulin G
1
Hydrocortisone
1
Disulfides
1
Dexamethasone
1
Carmustine
1
CT-P10
1
Bortezomib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Plasmablastic Lymphoma
×
Dexamethasone
×
Clear all
NCT04915248
2026-06-02
FIL_DALYA
Fondazione Italiana Linfomi - ETS
Phase 2
Recruiting
28 enrolled